JP2001525816A5 - - Google Patents

Download PDF

Info

Publication number
JP2001525816A5
JP2001525816A5 JP1998548911A JP54891198A JP2001525816A5 JP 2001525816 A5 JP2001525816 A5 JP 2001525816A5 JP 1998548911 A JP1998548911 A JP 1998548911A JP 54891198 A JP54891198 A JP 54891198A JP 2001525816 A5 JP2001525816 A5 JP 2001525816A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998548911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001525816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB1998/001343 external-priority patent/WO1998051344A1/en
Publication of JP2001525816A publication Critical patent/JP2001525816A/ja
Publication of JP2001525816A5 publication Critical patent/JP2001525816A5/ja
Withdrawn legal-status Critical Current

Links

JP54891198A 1997-05-12 1998-05-12 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制 Withdrawn JP2001525816A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85488197A 1997-05-12 1997-05-12
US08/854,881 1997-05-12
PCT/GB1998/001343 WO1998051344A1 (en) 1997-05-12 1998-05-12 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Publications (2)

Publication Number Publication Date
JP2001525816A JP2001525816A (ja) 2001-12-11
JP2001525816A5 true JP2001525816A5 (https=) 2005-12-02

Family

ID=25319772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54891198A Withdrawn JP2001525816A (ja) 1997-05-12 1998-05-12 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制

Country Status (6)

Country Link
EP (2) EP0980258A1 (https=)
JP (1) JP2001525816A (https=)
AU (1) AU7345798A (https=)
CA (1) CA2290021A1 (https=)
HK (1) HK1044887A1 (https=)
WO (1) WO1998051344A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
AU764629B2 (en) 1998-01-22 2003-08-28 Btg International Limited Inhibition of cytokine production
JP2002538170A (ja) * 1999-03-02 2002-11-12 セントコール, インコーポレイテッド 喘息の治療における抗−TNFα抗体
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
JP2003525612A (ja) * 2000-03-02 2003-09-02 ゼンコー TNF−α関連障害の処置のための変種TNF−αタンパク質の設計および発見
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
CN1713905A (zh) 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
JP2014518758A (ja) 2011-05-06 2014-08-07 バイオ−ラッド ラボラトリーズ インコーポレーティッド 迅速な温度変化のためのベイパーチャンバーを備えたサーマルサイクラー

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857553A1 (en) * 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

Similar Documents

Publication Publication Date Title
JP2000509635A5 (https=)
JP2000509637A5 (https=)
JP2000509912A5 (https=)
JP2000509942A5 (https=)
JP2000510751A5 (https=)
JP2000509587A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508841A5 (https=)
JP2001515546A5 (https=)
JP2001514552A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2002503177A5 (https=)
JP2001527597A5 (https=)
JP2001525816A5 (https=)
JP2000510969A5 (https=)
JP2000510247A5 (https=)
JP2002501484A5 (https=)
JP2002506477A5 (https=)
JP2000508836A5 (https=)
JP2002510991A5 (https=)
JP2000509818A5 (https=)
JP2000509520A5 (https=)